100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43DA050474
Award Date
7/1/20
Completion Date
4/30/22
Dollars Obligated
$606K
Overview
Activity
4
Transactions
4
Subawards
Similar Awards
Federal Agency
National Institute on Drug Abuse
Awardee
Hafion Inc. (G41ASXW94LC5)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Kansas, USA
Update #1
Update #2
PRODUCTION OF A NANOPARTICLE VACCINE TO AID IN SMOKING CESSATION
Posted 6/16/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
PRODUCTION OF A NANOPARTICLE VACCINE TO AID IN SMOKING CESSATION - SUMMARY ANTIBODY-MEDIATED THERAPIES ARE AN ATTRACTIVE ALTERNATIVE TO CURRENT SMOKING CESSATION STRATEGIES BECAUSE ANTIBODIES TARGET THE DRUG ITSELF TO PREVENT ITS CROSSING THE BLOOD BRAIN BARRIER WHILE EXHIBITING FAR FEWER SIDE EFFECTS. TO DATE, NICOTINE VACCINES HAVE MET WITH LIMITED SUCCESS IN CLINICAL TRIALS DUE TO THEIR LOW IMMUNOGENICITY. LIKE MOST SUBUNIT VACCINES, THEY HAVE HISTORICALLY SUFFERED FROM POOR EFFICACY DUE TO THEIR MONOMERIC NATURE. OUR APPROACH OVERCOMES THIS LIMITATION BY USING HAFION'S POLYVALENT ADJUVANT FUSION TECHNOLOGY (HAF) WHEREIN OPTIMALLY SIZED HYALURONIC ACID (HA) IS CONJUGATED TO A SUBUNIT VACCINE TO CREATE A POLYVALENT HA-ANTIGEN NANOPARTICLE DESIGNED FOR UPTAKE BY DENDRITIC CELLS AND SUBSEQUENT TRAFFICKING TO GERMINAL CENTERS IN THE LYMPH NODES TO ELICIT MAXIMUM IMMUNOLOGICAL MEMORY. THIS PROPOSAL WILL BRING TOGETHER SENIOR INVESTIGATORS FROM HAFION LLC, DESIGN-ZYME LLC, AND THE UNIVERSITY OF KANSAS. TOGETHER, WE WILL COMBINE THE RECENT SUCCESSES OF A NICOTINE HAPTEN, A SELF-ADJUVATING SUBUNIT ANTIGEN AND THE FORMATION OF NANOPARTICLES TO DEVELOP A NICOTINE VACCINE THAT PROVIDES LONG-TERM IMMUNOLOGICAL MEMORY. OUR APPROACH IMPROVES UPON THE CURRENT DESIGN OF NICOTINE VACCINES BY PURPOSEFULLY ELICITING IMMUNOLOGICAL MEMORY TO NICOTINE. TO DO THIS, HAFION IS COMBINING (1) A CUSTOMIZED NICOTINE HAPTEN THAT WILL BE (2) LINKED TO OUR PROPRIETARY ADJUVANT + HA COMPLEX KNOWN TO ELICIT IMMUNOLOGICAL MEMORY (DESIGN-ZYME LLC) BY (3) THE ATTACHMENT OF A CARRIER PROTEIN ANTIGEN THAT CONFERS BROAD PROTECTION AGAINST MULTIPLE SALMONELLA SEROTYPES. THE S. ENTERICA CARRIER PROTEIN ANTIGEN IS A SUBUNIT VACCINE DEVELOPED BY THE PICKING LABORATORY. THE GOAL OF THIS SBIR IS TO CREATE A SAFE, EFFECTIVE NICOTINE VACCINE WITH ADDITIONAL BACTERIAL PATHOGEN PROTECTION SUITABLE FOR ANIMAL TESTING AND EVENTUAL USE IN FDA CLINICAL TRIALS. THIS PROJECT WILL DEMONSTRATE FEASIBILITY BY ASSEMBLING COMPLETE NICOTINE + SALMONELLA VACCINE NANOPARTICLES WHICH WILL THEN BE TESTED FOR EFFICACY, ANTIBODY AFFINITY AND LONG-TERM IMMUNOGENICITY AGAINST NICOTINE AND SALMONELLA IN PHASE I. PHASE II OF THIS PROPOSAL WILL INVOLVE STUDIES TO PREPARE THE VACCINE CANDIDATE FOR CLINICAL TRIALS AS WELL AS ADDRESS LARGER SCALE PRODUCTION USING GLP AND GMP PRACTICES.
($574)
5/15/23
Not listed
PRODUCTION OF A NANOPARTICLE VACCINE TO AID IN SMOKING CESSATION - SUMMARY ANTIBODY-MEDIATED THERAPIES ARE AN ATTRACTIVE ALTERNATIVE TO CURRENT SMOKING CESSATION STRATEGIES BECAUSE ANTIBODIES TARGET THE DRUG ITSELF TO PREVENT ITS CROSSING THE BLOOD BRAIN BARRIER WHILE EXHIBITING FAR FEWER SIDE EFFECTS. TO DATE, NICOTINE VACCINES HAVE MET WITH LIMITED SUCCESS IN CLINICAL TRIALS DUE TO THEIR LOW IMMUNOGENICITY. LIKE MOST SUBUNIT VACCINES, THEY HAVE HISTORICALLY SUFFERED FROM POOR EFFICACY DUE TO THEIR MONOMERIC NATURE. OUR APPROACH OVERCOMES THIS LIMITATION BY USING HAFION'S POLYVALENT ADJUVANT FUSION TECHNOLOGY (HAF) WHEREIN OPTIMALLY SIZED HYALURONIC ACID (HA) IS CONJUGATED TO A SUBUNIT VACCINE TO CREATE A POLYVALENT HA-ANTIGEN NANOPARTICLE DESIGNED FOR UPTAKE BY DENDRITIC CELLS AND SUBSEQUENT TRAFFICKING TO GERMINAL CENTERS IN THE LYMPH NODES TO ELICIT MAXIMUM IMMUNOLOGICAL MEMORY. THIS PROPOSAL WILL BRING TOGETHER SENIOR INVESTIGATORS FROM HAFION LLC, DESIGN-ZYME LLC, AND THE UNIVERSITY OF KANSAS. TOGETHER, WE WILL COMBINE THE RECENT SUCCESSES OF A NICOTINE HAPTEN, A SELF-ADJUVATING SUBUNIT ANTIGEN AND THE FORMATION OF NANOPARTICLES TO DEVELOP A NICOTINE VACCINE THAT PROVIDES LONG-TERM IMMUNOLOGICAL MEMORY. OUR APPROACH IMPROVES UPON THE CURRENT DESIGN OF NICOTINE VACCINES BY PURPOSEFULLY ELICITING IMMUNOLOGICAL MEMORY TO NICOTINE. TO DO THIS, HAFION IS COMBINING (1) A CUSTOMIZED NICOTINE HAPTEN THAT WILL BE (2) LINKED TO OUR PROPRIETARY ADJUVANT + HA COMPLEX KNOWN TO ELICIT IMMUNOLOGICAL MEMORY (DESIGN-ZYME LLC) BY (3) THE ATTACHMENT OF A CARRIER PROTEIN ANTIGEN THAT CONFERS BROAD PROTECTION AGAINST MULTIPLE SALMONELLA SEROTYPES. THE S. ENTERICA CARRIER PROTEIN ANTIGEN IS A SUBUNIT VACCINE DEVELOPED BY THE PICKING LABORATORY. THE GOAL OF THIS SBIR IS TO CREATE A SAFE, EFFECTIVE NICOTINE VACCINE WITH ADDITIONAL BACTERIAL PATHOGEN PROTECTION SUITABLE FOR ANIMAL TESTING AND EVENTUAL USE IN FDA CLINICAL TRIALS. THIS PROJECT WILL DEMONSTRATE FEASIBILITY BY ASSEMBLING COMPLETE NICOTINE + SALMONELLA VACCINE NANOPARTICLES WHICH WILL THEN BE TESTED FOR EFFICACY, ANTIBODY AFFINITY AND LONG-TERM IMMUNOGENICITY AGAINST NICOTINE AND SALMONELLA IN PHASE I. PHASE II OF THIS PROPOSAL WILL INVOLVE STUDIES TO PREPARE THE VACCINE CANDIDATE FOR CLINICAL TRIALS AS WELL AS ADDRESS LARGER SCALE PRODUCTION USING GLP AND GMP PRACTICES.
$128.9k
6/29/21
Not listed
PRODUCTION OF A NANOPARTICLE VACCINE TO AID IN SMOKING CESSATION - SUMMARY ANTIBODY-MEDIATED THERAPIES ARE AN ATTRACTIVE ALTERNATIVE TO CURRENT SMOKING CESSATION STRATEGIES BECAUSE ANTIBODIES TARGET THE DRUG ITSELF TO PREVENT ITS CROSSING THE BLOOD BRAIN BARRIER WHILE EXHIBITING FAR FEWER SIDE EFFECTS. TO DATE, NICOTINE VACCINES HAVE MET WITH LIMITED SUCCESS IN CLINICAL TRIALS DUE TO THEIR LOW IMMUNOGENICITY. LIKE MOST SUBUNIT VACCINES, THEY HAVE HISTORICALLY SUFFERED FROM POOR EFFICACY DUE TO THEIR MONOMERIC NATURE. OUR APPROACH OVERCOMES THIS LIMITATION BY USING HAFION'S POLYVALENT ADJUVANT FUSION TECHNOLOGY (HAF) WHEREIN OPTIMALLY SIZED HYALURONIC ACID (HA) IS CONJUGATED TO A SUBUNIT VACCINE TO CREATE A POLYVALENT HA-ANTIGEN NANOPARTICLE DESIGNED FOR UPTAKE BY DENDRITIC CELLS AND SUBSEQUENT TRAFFICKING TO GERMINAL CENTERS IN THE LYMPH NODES TO ELICIT MAXIMUM IMMUNOLOGICAL MEMORY. THIS PROPOSAL WILL BRING TOGETHER SENIOR INVESTIGATORS FROM HAFION LLC, DESIGN-ZYME LLC, AND THE UNIVERSITY OF KANSAS. TOGETHER, WE WILL COMBINE THE RECENT SUCCESSES OF A NICOTINE HAPTEN, A SELF-ADJUVATING SUBUNIT ANTIGEN AND THE FORMATION OF NANOPARTICLES TO DEVELOP A NICOTINE VACCINE THAT PROVIDES LONG-TERM IMMUNOLOGICAL MEMORY. OUR APPROACH IMPROVES UPON THE CURRENT DESIGN OF NICOTINE VACCINES BY PURPOSEFULLY ELICITING IMMUNOLOGICAL MEMORY TO NICOTINE. TO DO THIS, HAFION IS COMBINING (1) A CUSTOMIZED NICOTINE HAPTEN THAT WILL BE (2) LINKED TO OUR PROPRIETARY ADJUVANT + HA COMPLEX KNOWN TO ELICIT IMMUNOLOGICAL MEMORY (DESIGN-ZYME LLC) BY (3) THE ATTACHMENT OF A CARRIER PROTEIN ANTIGEN THAT CONFERS BROAD PROTECTION AGAINST MULTIPLE SALMONELLA SEROTYPES. THE S. ENTERICA CARRIER PROTEIN ANTIGEN IS A SUBUNIT VACCINE DEVELOPED BY THE PICKING LABORATORY. THE GOAL OF THIS SBIR IS TO CREATE A SAFE, EFFECTIVE NICOTINE VACCINE WITH ADDITIONAL BACTERIAL PATHOGEN PROTECTION SUITABLE FOR ANIMAL TESTING AND EVENTUAL USE IN FDA CLINICAL TRIALS. THIS PROJECT WILL DEMONSTRATE FEASIBILITY BY ASSEMBLING COMPLETE NICOTINE + SALMONELLA VACCINE NANOPARTICLES WHICH WILL THEN BE TESTED FOR EFFICACY, ANTIBODY AFFINITY AND LONG-TERM IMMUNOGENICITY AGAINST NICOTINE AND SALMONELLA IN PHASE I. PHASE II OF THIS PROPOSAL WILL INVOLVE STUDIES TO PREPARE THE VACCINE CANDIDATE FOR CLINICAL TRIALS AS WELL AS ADDRESS LARGER SCALE PRODUCTION USING GLP AND GMP PRACTICES.
$128.9k
6/29/21
Not listed
PRODUCTION OF A NANOPARTICLE VACCINE TO AID IN SMOKING CESSATION
$220.1k
6/16/20